SKI Domain Analysis
SETBP1 SKI homology domain hotspot mapping and co-occurrence
SKI Domain
193 patients
Hotspot positions 858-871
Non-SKI
29 patients
G870S Rank
#2
136 samples (88 patients), after D868N (195 samples)
G870S in SKI
40%
88 of 221 SKI-mutated patients (GENIE myeloid recount)
DNMT3A-EZH2
0.999 STRING
Top score, tied with 2 other pairs
SKI vs Non-SKI Co-occurrence
Source: GENIE v19.0
Loading protein domain plot...
Source: GENIE v19.0 sample counts; AT-hooks from UniProt Q9Y6X0
SKI Domain Hotspot Map
The SETBP1 mutation hotspot
1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
spans codons 858-871 and contains the
beta-TrCP degron (D-S-G-I-G-T, residues 868-873 in UniProt Q9Y6X0).
Somatic SETBP1 mutations in myeloid malignancies
2[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
cluster at key residues: D868,
S869, G870, I871. Mutations at these positions disrupt degron
recognition by the SCF(beta-TrCP) E3 ubiquitin ligase complex,
preventing ubiquitination and proteasomal degradation. The result is
nuclear SETBP1 accumulation, which inhibits PP2A tumor suppressor
activity 1[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
and upregulates
HOXA9/HOXA10 transcription factors — a key oncogenic axis in
myeloid neoplasms.
| Position | Wildtype | Most Common Mutation | GENIE samples | Mechanism |
|---|---|---|---|---|
| 858 | E | E858K | 5 | Degron disruption |
| 868 | D | D868N | 195 | Degron disruption |
| 869 | S | S869R (also S869N, S869G: 3 each) | 5 | Degron disruption |
| 870 | G | G870S | 136 | Degron disruption |
| 871 | I | I871T | 28 | Degron disruption |
SETBP1 Pairwise Partners
| Partner | Co-mutated | O/E | p-value | Direction |
|---|---|---|---|---|
| CSF3R | 18 | 10.00 | 1.1e-13 | Co-occurring |
| CBL | 32 | 4.85 | 7.1e-14 | Co-occurring |
| ASXL1 | 145 | 4.67 | 4.4e-71 | Co-occurring |
| EZH2 | 36 | 4.07 | 3.8e-13 | Co-occurring |
| SRSF2 | 79 | 3.73 | 6.4e-27 | Co-occurring |
| U2AF1 | 39 | 3.46 | 5.8e-12 | Co-occurring |
| GATA2 | 11 | 2.54 | 0.004 | Co-occurring |
| PTPN11 | 15 | 2.51 | 9.6e-4 | Co-occurring |
| NRAS | 29 | 2.19 | 6.9e-5 | Co-occurring |
| RUNX1 | 39 | 1.95 | 4.2e-5 | Co-occurring |
| IDH1 | 1 | 0.13 | 0.005 | Mutually exclusive |
| NPM1 | 2 | 0.16 | 3.6e-4 | Mutually exclusive |
| JAK2 | 14 | 0.42 | 8.3e-5 | Mutually exclusive |
| TP53 | 14 | 0.55 | 0.014 | Mutually exclusive |
| DDX41 | 2 | 4.26 | 0.079 | Neutral |
| SMC3 | 4 | 3.25 | 0.034 | Neutral |
| RAD21 | 4 | 1.73 | 0.295 | Neutral |
| STAG2 | 11 | 1.68 | 0.102 | Neutral |
| ZRSR2 | 6 | 1.45 | 0.311 | Neutral |
| BCOR | 9 | 1.09 | 0.719 | Neutral |
| KRAS | 8 | 1.05 | 0.851 | Neutral |
| DNMT3A | 30 | 1.04 | 0.840 | Neutral |
| TET2 | 34 | 0.93 | 0.714 | Neutral |
| PHF6 | 5 | 0.93 | 1.000 | Neutral |
| IDH2 | 12 | 0.92 | 0.885 | Neutral |
| MPL | 3 | 0.84 | 1.000 | Neutral |
| FLT3 | 10 | 0.81 | 0.556 | Neutral |
| SF3B1 | 8 | 0.59 | 0.120 | Neutral |
| CALR | 4 | 0.53 | 0.258 | Neutral |
| CEBPA | 2 | 0.44 | 0.332 | Neutral |
| WT1 | 3 | 0.42 | 0.124 | Neutral |
| BCORL1 | 0 | 0.00 | 0.036 | Neutral |
| SMC1A | 0 | 0.00 | 0.639 | Neutral |
Source: Fisher's exact test (two-sided)
with Benjamini-Hochberg correction. Panel-adjusted denominators.
GENIE v19.0 17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
,
222 SETBP1-mutated patients (GENIE myeloid
and histiocytic cancer types, one sample per patient).
EZH2 Interaction
STRING v12.0 protein-protein interaction analysis reveals DNMT3A-EZH2
with the top confidence score in the network (0.999, tied with
DNMT3A-DNMT3L and U2AF1-SRSF2 among 77 interactions), and the strongest
link between two of the patient's mutated genes.
Both are epigenetic regulators — DNMT3A controls DNA methylation,
EZH2 controls histone methylation (H3K27me3)
9
[9] T 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010)
10[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
.
Their co-mutation creates a bidirectional epigenetic collapse: loss of
DNA methylation fidelity (DNMT3A R882H) combined with loss of
Polycomb-mediated gene silencing (EZH2 V662A LoF).
SETBP1 connects to this axis as an epigenetic hub
3
[3] R 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018)
through HCF1/KMT2A interaction
and PP2A inhibition 1[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
leading to
HOXA9/HOXA10 upregulation. Runx1 repression
5[5] BA 2016
Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. Leukemia (2016)
further compounds the
transcriptional deregulation. With both DNMT3A (which also upregulates
HOXA via hypomethylation) and SETBP1 converging on HOXA, the
oncogenic signaling is amplified.
The Jaccard pathway similarity of SETBP1-IDH2 (0.588) and DNMT3A-IDH2
(0.590) is nearly identical. IDH2 and SETBP1 are not mutually exclusive
in this GENIE dataset (O/E 0.92, not significant; see the partner table),
so these values say nothing about an exclusivity mechanism.
Recent evidence that SETBP1 can act as a first-hit driver
4
[4] I 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood (2024)
in myeloproliferative disorders
with bone marrow fibrosis expands the mechanistic framework: SETBP1
mutations may not only cooperate with pre-existing epigenetic lesions
but can independently initiate clonal expansion.
Source: STRING v12.0 protein-protein
interaction database. Jaccard similarity computed from Reactome and
KEGG pathway memberships.
Research Context
Piazza et al. (2013) found 92% of SETBP1 mutations in their series at codons 858-871.
In GENIE v19.0 myeloid data, 90.7% of SETBP1 coding mutation calls (431 of 475) fall there.
G870S is the second most common hotspot variant (136 samples, 88 patients), after D868N
(195 samples, 101 patients).
SKI-domain mutations show consistently amplified co-occurrence ratios compared to non-SKI
mutations: CSF3R O/E rises from 10.00 overall to 10.76 within the SKI subset, and CBL
from 4.85 to 5.41. The SKI domain hotspot defined by Makishima et al. (2013) concentrates
mutations at positions associated with monosomy 7 and poor prognosis. The SKI-domain
enrichment pattern (193 of 222 SETBP1-mutated patients) validates the biological
significance of this region.
References
- Piazza R et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
- Makishima H et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013). PubMed
- AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov (2017). DOI
- Piazza R et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018). PubMed
- Crespiatico I, Zaghi M, Mastini C, et al. (senior author Piazza R). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood (2024). PubMed
- Ernst T et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010). PubMed
- Vishwakarma BA et al. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. Leukemia (2016). PubMed
- Chase A, Score J, Lin F, et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020). DOI